Key result
Serum omentin-1 levels were inversely associated with the presence and angiographic severity of coronary artery disease in patients with metabolic syndrome.
Why the study?
Are serum omentin-1 levels associated with the presence and severity of CAD in patients with metabolic syndrome?
Observational (n=221)
Are serum omentin-1 levels associated with the presence and severity of CAD in patients with metabolic syndrome?
Serum omentin-1 may serve as a potential biomarker to predict the development and progression of CAD in patients with metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Supports omentin-1 as potential CAD biomarker in metabolic syndrome; hypothesis-generating, requires prospective validation before clinical use.
CONTEXT: Omentin-1, an adipokine secreted from visceral adipose tissue, has been reported to be associated with coronary artery disease (CAD) and metabolic disorders. OBJECTIVE: To clarify the relationship between serum omentin-1 levels and the presence and severity of CAD in patients with metabolic syndrome (MetS). METHODS: We measured serum omentin-1 levels in 175 consecutive patients with MetS and in 46 controls. RESULTS: Serum omentin-1 levels are inversely associated with the presence and angiographic severity of CAD in MetS patients. CONCLUSIONS: Serum omentin-1 might be a potential biomarker to predict the development and progression of CAD in MetS patients.
No takes yet. Share an insight, caveat, or question.
Shang et al. (2011) conducted an observational in Metabolic syndrome and coronary artery disease (n=221). Serum omentin-1 levels vs. Controls was evaluated on Presence and angiographic severity of coronary artery disease. Serum omentin-1 levels were inversely associated with the presence and angiographic severity of coronary artery disease in patients with metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: